Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It was polymedix and now they are in bankruptcy. They were developing a novel antibiotic and then had to sell assets. Cellceutix now bought the drug and will develop it themselves. So basically the drug is alive just that all my shares are worth shit. The other company swoops in buys the drug at a huge discount and then gets to run with it. What crap. Now gnbt is a red flag all the same...signals of trouble getting additional money to continue additional trials. If they don't get additional monies then they will go under like polymedix did. Then through bankruptcy selling assets process, some other company can buy the tech and the drugs to develop on their own. Then the option will be to buy stock of the new company.
Ugh, if only we had better news in a positive light to eliminate the extreme negative thoughts that I am having.
I will do the same but it's not that easy. I had one last year that went belly up and I can't afford a repeat. Down 90% over night. I guess if I can't afford the risk then I should get out while I can but the potential of AE37 is extraordinary. Ugh
Thx, that's what it looked like. Is that still a good sign for shareholders? That company execs are willing to work for shares instead of large monetary compensation? Or is it all a sham?
some SEC filings.....
http://investor.generex.com/sec.cfm
what does this stuff mean?????
I don't need to see a dollar anytime soon. Let's start with six or seven cents pps first
They shouldn't have a problem getting institutional funding/backing imo since they would be getting a good deal. Stock is dirt cheap.
How are those deals made?
Yeah, AE37 sounds more interesting...
Man o man, who the hell knows. This crap takes years to come to fruition. Heck, each phase takes years. AE37 sounds interesting but there is so much that goes into it. Military hospital and other enrollment sites all over the place. The md anderson principal investigator is intrigued by findings. So is all this misleading? They havent released more info yet. i know they said the fall. this is the fall but do they mean nov or dec? The company is like any other biotech in that they are in the red for years. What are the options? They go under from lack of funding or they actually get somewhere and the stock takes off? In one hand epic failure and the other hand great success. It just bothers me that so many people involved like the researchers devote their lives to this stuff for what? They can't all be working on a false hope can they? I guess they can if they get their paycheck from us buying shares. Must be a sweet gig...to get paid to tabulate b.s. and lie cheat steal??? Is that what is happening? I can't make heads or tails for the life of me. Message boards bash stuff but they bash a lot of stuff. PR is the opposite and put a shine to shit. Where is the middle?
I saw it. Neg comments. What is the risk for bankruptcy? High , low?
u have the link?
All sorts of info in this...
http://investor.generex.com/secfiling.cfm?filingid=1554795-13-602
i hope so. ffffffffffffffffffffffffff, it just dipped under 0.03
Ugh, everything is red <thumbs down>
news....
WORCESTER, Mass. and TORONTO, Sept. 27, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today provided an update in respect of the previously announced conference call on the Company's proprietary Generex Oral-lyn(TM) buccal insulin spray program. The call will focus on recent developments, the planned Generex Oral-lyn(TM) formulation and process improvements, and the go-forward strategy for the expansion of the Generex Diabetes Program, including diagnostics and therapeutics for type 1 and type 2 patients as well as pre-diabetes, and potential therapeutics for reducing the complications of diabetes.
Earlier this year, the Company announced that its Indian licensee, Shreya Life Sciences Pvt. Ltd. (www.shreya.co.in), had completed a local Phase III trial of the buccal insulin product (branded as Oral Recosulin(R) in India) and submitted the dossier to the Drugs Controller General (India) (DCGI), Central Drugs Standard Control Organization, Director General of Health Services, Ministry of Health and Family Welfare, Government of India.
The trial, conducted at 14 sites in India with 209 patients (with a 95% completion rate), demonstrated the effectiveness and non-inferiority of the product in comparison to injected insulin and that the product was well-tolerated and a preferred alternative to injection.
In conjunction with its review of the dossier, the DCGI recently requested that the submission be augmented by the inclusion of some stability data from previous studies undertaken by Generex. The Company is in the process of collecting and formatting that data and expects to provide it to Shreya within the next two weeks.
As Generex wishes the conference call to be as informative, comprehensive, and up-to-date as possible, management considers it appropriate to schedule the call once the DCGI's review of the dossier is complete. A further announcement with the date and other particulars of the call will be made in due course.
I dont mind waiting too much. it still fluctuates so that means it can still be traded and can make money on subtle ups and downs....only thng i do want to avoid is a sinking ship or nail in the coffin situation. is this thing doomed? will they still be around for a while???? i've been burned by others and all this negative attitude is a huge red flag. I can see where it comes from since anyone who invested a while ago is now screwed by it getting so low.
looks to be rebounding from the dip it had the last few weeks. wooo hooo!
There has only been good press for the last 9 months, Y or N? lots of if's on the horizon but nothing detrimental as far as I can see. Am I missing something? I know that it has been sitting for years...is the horizon getting closer or is it still years away from any real action?
0.005 above what it's trading now...
patience is the hardest part it seems. oral-lyn was approved in the past so it should be approved again. they just had hoops to jump through with doing that trial in India.
wish it would happen soon though and get back up to my average price. i am snagging more shares on the down turn but come on....cant hold up like this for long
thats what i am banking on. Good news at that time should get a ton of interest. i dont see how it wouldnt explode at that time. the most recent stuff about the prostate cancer patients sounds very good. i guess that it is not statistaclly significant as in they cant jump to any conclusions but it is very interesting all the same...
what they said:
"Intriguingly, none of the patients in this study belonging to the intermediate or high risk groups as determined by Gleason score developed metastasis, even though metastases would have been predicted to occur in roughly 27% of nine intermediate-risk patients and 60% of eight high-risk patients based upon historical data from patients with these stages of disease. In addition, the median overall survival of six patients with metastatic disease was 89 months, which considerably exceeds that usually observed in this group historically.
"While clearly not designed as an efficacy study, the lack of disease progression observed in this Phase I trial is encouraging," commented Dr. Eric von Hofe, Ph.D., President of Antigen Express. "The longevity of the immunological response speaks to the robust yet specific mechanism of action of AE37 and the technology platform upon which it was designed," he added."
in agony with all the waiting...I dont know if I can hold out until mid fall for supposed good news.
Aha, I found a way. On the iPhone I had to swipe left on the message and then it let me click "remove". It wasn't there before the swipe.
Thanks
Some sort of general alerts are in my mail box and look like unread messages even though I have read them. Is there a way to clear them?
Other areas allow a reset.
How do you clear alerts from messages?
Hah, MNKD lost ground and then some....Oralyn may have no other rivals? Is anyone else trying to make an inhaled insulin?
I too wonder about Oralyn in the u.s.
Recently Mannkind had progress with their ph3 inhaled insulin, Afrezza. Their stock had a bunch of movement.
To me, Oralyn sounds better because it is not deposited in the lungs. It absorbs in the upper respiratory or actually oral cavity/throat. Whereas other companies (Pfizer from what I understand) failed because products deposited further down had encountered complications with the patients. Also, MNKD had issues with Afrezza in the past. As I understand they had to submit requests a few times and were getting rejected for various things earlier?
Oralyn in India was going to be approved earlier until they required an in country study before they would review data. Apparently that is what the hold up was and the delay for the last few years. Seems that things are getting closer with Oralyn there.
Overall it seems that oral insulins have a ton of hurdles to get past. Not an easy road for any maker. Hence why attempts were given up by others. I feel that overall it is easier to produce the injectable insulins even though inhaled would definitely be better for the patient.
Regardless, I am crossing my fingers for GNBT. AE37 can be huge. immunotherapies will be king when it comes to treating cancer in the coming years. More and more with each year. Just who will get there faster and more successfully? Large variety of approaches and all these new IPOs this year promising new drugs. i vote for GNBT as they are already well invested into the whole deal. Big money, big money, no whammie, no whammie!!!
PH II data comes out in the fall. stock should move very nicely from that. will use the interim to scoop as many shares as I can allow in my portfolio.
I anticipate PH II release to be quite positive.
then we'll see what partner they can match up with. then PH III will start. earlier in the presentation they mention that a typical study comparing against trastuzumab would take a pretty large number of patients. whoever it was suggested designing a trial that targets more at risk patients. this would allow for a smaller trial...which would cost less to do. the negative is that it may mean a more narrow FDA indication for use. not necessarily a bad thing. would mean the ball could get rolling faster.
also sometime during this time they hope that the stock will rise a bit to then maybe do a reverse stock split (they have that option in their back pocket). they mentioned that they would rather the stock be higher before they attempt something like that so that the split is not so extreme (ratio wise). the hope being that they can get back on a bigger exchange.
this is just my interpretation of what I heard. A lot of info was presented.
first 15 minutes are crap. after that it gets very informative...AE37 sounds remarkable.
I only caught the last couple minutes...a question was asked about what they could share about possible partnerships for phase III.
Response was something like this:
...they will get current phase II data together in the fall. Then they will present the dataset to secure a partnership for phase III.
Sounded that they have a few possiblities for partnering but who knows.
guess it hangs on what they will release in the dataset. like what it actually shows and what kind of interests spark from that.
i will try to listent to the whole thing but their site isnt letting me at the moment.
I only caught the end of the call. anyone listen to the whole thing? anything good discussed?
Third quarter better be worth the wait...
I get a sketchy feeling too. I understand being hopeful and then being stupid....i vote for not being stupid. I'll find moments to get out and then get the F out. at least a good chunk of the way out. just sucks becuase this can be huge. Typical biotech research company problem. they are damn money pit and are red for years...then go bankrupt or whatever like nose dive and are worthless.
just cant help to feel that they are on the verge of something positive.
you've been waiting for 3 years, damn. I dont know if I could have that kind of patience. I started buying this one in 2012 and and itching for something to happen. been debating on ditching it and moving on to something else...
but they do have that conference call this coming week and they also mention that something should happen this fall...
just a little more time! crossing my fingers!
when will something happen?
one week for more AE37 news and what about India and the oral insulin? by end of year? DCGI needs to approve it now. I have no patience for dilly dallying. They are a long way away from making any kind of money but India has got to approve the med first. If they do then they have funds to keep going with AE37, right? otherewise, its just like any other biotech money pit with no return in any foreseeable future? what are their options to proceed with AE37? get institutional investors, partner with some big Pharma, or what? go bankrupt? I have been burned before.
Cant afford a repeat.
So they have an upcoming conference call to discuss the phase II of AE37. From what Dr. Mittendorf already said in that ASCO interview I would expect it to be promising. How will this fair in making it go to phase III? who knows.
Biotherapies will be huge over the next decade. Apparently better that regular chemo with less side effects. Using your own body to produce an immune response to fight cancer versus takes toxic chemo meds or using radio therapy. Sounds ideal. Many companies are trying to accomplish this. Will GNBT and the Antigen Express technology be the ones to make breakthroughs? Quite a gamble. Their approach is a little different than the other companies.
The science makes sense but it will take business skills to make it real. Can they continue to fund this project?
Also the whole Oral-lyn push in India is promising. They make it sound that Shreya pharma expects it to get approved.
This would be a big deal if they can start selling this product. Bio Tech is always in the red until they can actually start selling and making money.
Are they too diluted? I want hundreds of thousands of shares.
I am crossing my fingers with this one.